GlassScriptPhysician profile
Jeanne Edwards
NPI 1740223403
$1,287.41
in general payments reported to CMS, 2019-2025
21 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.77 · 2021: $13.65 · 2022: $191 · 2023: $194 · 2024: $695 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.55 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $223.02 | 2023-2025 | |
| Lundbeck LLC | $216.73 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $110.57 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $101.92 | 2024-2025 | Kisunla, Reyvow, Emgality |
| Novartis Pharmaceuticals Corporation | $96.11 | 2022-2023 | |
| Ucb, INC. | $83.48 | 2019-2024 | Nayzilam |
| Pfizer INC. | $68.84 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $59.91 | 2022 | |
| Scilex Pharmaceuticals INC. | $40.13 | 2023 | Ztlido |
| Argenx US, INC. | $35.95 | 2024 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $35.13 | 2024 | Rexulti |
| Sk Life Science, INC. | $27.84 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.52 | 2022 | |
| Amgen INC. | $27.27 | 2023 | Aimovig |
| Amneal Pharmaceuticals LLC | $25.17 | 2024 | Rytary |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.81 | 2023 | Percept PC Brainsense |
| Corium, LLC | $21.12 | 2023 | Adlarity |
| Csl Behring | $20.07 | 2022 | |
| Abbvie INC. | $15.10 | 2022 | |
| Currax Pharmaceuticals LLC | $15.07 | 2024 | Onzetra Xsail |
| Biohaven Pharmaceuticals, INC. | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanne Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.